Press Releases

    • DEC 09 2014

    Multiple Abstracts Selected for 2014 ASH Annual Meeting Demonstrating Safety and Efficacy of Oncoceutics’ ONC201

    Hummelstown, PA (December 8, 2014) – Oncoceutics, Inc. announced that seven multi-investigator abstracts were selected for the 2014 annual meeting of the American Society of Hematology (ASH) that is being held December 6-9 in San Francisco, CA. Taken together, these abstracts ubiquitously describe compelling efficacy and safety of ONC201 in pre-clinical settings across the spectrum

    • NOV 21 2014

    Oncoceutics Initiates Collaborations with Fox Chase Cancer Center

    Hummelstown, PA (November 7, 2014) – Oncoceutics, Inc., announces the initiation of multifaceted preclinical collaborations with Fox Chase Cancer Center on its lead compound ONC201. These programs are supported in part by an NIH RO1 grant to study the mechanism of action of the first-in-class ONC201 anti-cancer drug candidate that was awarded to Wafik El-Deiry,

    • NOV 06 2014

    Oncoceutics Opens Office at University City Science Center

    Hummelstown, PA (November 4, 2014) – Oncoceutics, Inc., announces the expansion of its operations with the opening of an office at the University City Science Center in Philadelphia. The new office space will support the growth of its team as it transitions to a clinical stage company with multiple development programs. The company’s lead compound

    • SEP 23 2014

    Oncoceutics Closes Financing Round to Begin ONC201 Clinical Programs

    Hummelstown, PA (September 23, 2014) – Oncoceutics, Inc., announces the closing of a funding round led by Spring Mountain Capital, LP (SMC) with additional private investors’ participation. The private placement was substantially oversubscribed. Oncoceutics will use the proceeds of the financing in conjunction with non-dilutive grant awards, public- private partnerships and academic alliances to accelerate